Recent and ongoing clinical trials show cardioprotective and nephroprotective effects of treatment with non-steroidal selective MR antagonists in CKD patients and further underscore the important role of the MR in CKD-related cardiovascular damage [17]. Here, NR3C2 is linked to chronic kidney disease.